Luye Pharma Group has announced that its CNS drug, Seroquel XR, has received approval from the official Chines...
A China Class 1 New Compound Starting Phase I Clinical Trials
Luye Pharma s independently developed drug LY01005 has entered phase III clinical trials for prostate cancer ...
Luye Pharma’s core CNS products, ‘Rivastigmine Transdermal Patches’, have been completed and approved by th...
On June 22nd in Hong Kong, Luye Pharma Group hosted a conference to unveil their Global Collaboration Strategy...
Luye Medical Group announced that it has recently completed a majority equity investment in Novena Heart Centr...
TOP